{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:16:47Z","timestamp":1789597007694,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189823"],"award-info":[{"award-number":["UG1CA189823"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["U10CA025224, U10CA035090, U10CA035101, U10CA035103, U10CA035113, U10CA035119, U10CA035267, U10CA035269, U10CA035415, U10CA035431, U10CA035448, U10CA037404, U10CA037417, U10CA052352, U10CA063848, U10CA063849, U10CA180790, UG1CA189863, and UG1CA189971"],"award-info":[{"award-number":["U10CA025224, U10CA035090, U10CA035101, U10CA035103, U10CA035113, U10CA035119, U10CA035267, U10CA035269, U10CA035415, U10CA035431, U10CA035448, U10CA037404, U10CA037417, U10CA052352, U10CA063848, U10CA063849, U10CA180790, UG1CA189863, and UG1CA189971"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00520-017-3960-9","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T20:19:53Z","timestamp":1511295593000},"page":"1335-1343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)"],"prefix":"10.1007","volume":"26","author":[{"given":"Debra L.","family":"Barton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne T.","family":"Shuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Dockter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Atherton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Thielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen N.","family":"Birrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby A.","family":"Terstriep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Lafky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"issue":"4","key":"3960_CR1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ecl.2004.07.003","volume":"33","author":"CR Gracia","year":"2004","unstructured":"Gracia CR, Freeman EW (2004) Acute consequences of the menopausal transition: the rise of common menopausal symptoms. Endocrinol Metab Clin N Am 33(4):675\u2013689. \n                    https:\/\/doi.org\/10.1016\/j.ecl.2004.07.003","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"2","key":"3960_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ogc.2017.02.008","volume":"44","author":"JL Bacon","year":"2017","unstructured":"Bacon JL (2017) The menopausal transition. Obstet Gynecol Clin N Am 44(2):285\u2013296. \n                    https:\/\/doi.org\/10.1016\/j.ogc.2017.02.008","journal-title":"Obstet Gynecol Clin N Am"},{"issue":"10021","key":"3960_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(15)01169-1","volume":"387","author":"PA Ganz","year":"2016","unstructured":"Ganz PA, Cecchini RS, Julian TB et al (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10021):857\u2013865","journal-title":"Lancet"},{"issue":"2","key":"3960_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10549-007-9548-1","volume":"107","author":"D Cella","year":"2008","unstructured":"Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107(2):167\u2013180. \n                    https:\/\/doi.org\/10.1007\/s10549-007-9548-1","journal-title":"Breast Cancer Res Treat"},{"key":"3960_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-3-319-16366-6_9","volume":"862","author":"DL Barton","year":"2015","unstructured":"Barton DL, Ganz PA (2015) Symptoms: menopause, infertility and sexual health. Adv Exp Med Biol 862:115\u2013141. \n                    https:\/\/doi.org\/10.1007\/978-3-319-16366-6_9","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"3960_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1743-6109.2008.01052.x","volume":"6","author":"LA Lara","year":"2009","unstructured":"Lara LA, Useche B, Ferriani RA et al (2009) The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med 6(1):30\u201339. \n                    https:\/\/doi.org\/10.1111\/j.1743-6109.2008.01052.x","journal-title":"J Sex Med"},{"issue":"1","key":"3960_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1522-5720(03)00049-7","volume":"4","author":"DM Leclair","year":"2002","unstructured":"Leclair DM, Ananjarajah G (2002) Review article: Effects of estrogen deprivation: vasomotor symptoms, urogenital atrophy, and psychobiologic effects. Clinics in Fam Pract 4(1):27\u201339. \n                    https:\/\/doi.org\/10.1016\/S1522-5720(03)00049-7","journal-title":"Clinics in Fam Pract"},{"issue":"1","key":"3960_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/gme.0b013e3181a95581","volume":"17","author":"DF Archer","year":"2010","unstructured":"Archer DF (2010) Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 17(1):194\u2013203","journal-title":"Menopause"},{"issue":"1","key":"3960_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/gme.0b013e31821f92df","volume":"19","author":"O Tan","year":"2012","unstructured":"Tan O, Bradshaw K, Carr BR (2012) Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause 19(1):109\u2013117","journal-title":"Menopause"},{"issue":"3 Pt 1","key":"3960_CR10","first-page":"355","volume":"14","author":"North American Menopause Society","year":"2007","unstructured":"North American Menopause Society (2007) The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause (New York) 14(3 Pt 1):355\u2013369 quiz 370\u2013351","journal-title":"Menopause (New York)"},{"issue":"3","key":"3960_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00042192-200205000-00006","volume":"9","author":"RJ Santen","year":"2002","unstructured":"Santen RJ, Pinkerton JV, Conaway M et al (2002) Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 9(3):179\u2013187","journal-title":"Menopause"},{"issue":"4","key":"3960_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/annonc\/mdj127","volume":"17","author":"A Kendall","year":"2006","unstructured":"Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17(4):584\u2013587. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdj127","journal-title":"Ann Oncol"},{"issue":"3","key":"3960_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JOP.2011.000352","volume":"8","author":"S Wills","year":"2012","unstructured":"Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, Hayes DF, Decker DA (2012) Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 8(3):144\u2013148. \n                    https:\/\/doi.org\/10.1200\/JOP.2011.000352","journal-title":"J Oncol Pract"},{"issue":"6","key":"3960_CR14","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1210\/jcem.86.6.7524","volume":"86","author":"T Naessen","year":"2001","unstructured":"Naessen T, Rodriguez-Macias K, Lithell H (2001) Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab 86(6):2757\u20132762. \n                    https:\/\/doi.org\/10.1210\/jcem.86.6.7524","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3960_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0002-9378(97)70448-4","volume":"177","author":"T Naessen","year":"1997","unstructured":"Naessen T, Berglund L, Ulmsten U (1997) Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. Am J Obstet Gynecol 177(1):115\u2013119. \n                    https:\/\/doi.org\/10.1016\/S0002-9378(97)70448-4","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"3960_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/jamaoncol.2016.3934","volume":"3","author":"K Reeder-Hayes","year":"2017","unstructured":"Reeder-Hayes K, Muss HB (2017) Vaginal estrogens and aromatase inhibitors: how safe is safe enough? JAMA Oncol 3(3):305\u2013306. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2016.3934","journal-title":"JAMA Oncol"},{"issue":"5","key":"3960_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/gme.0b013e31819e85c6","volume":"16","author":"F Labrie","year":"2009","unstructured":"Labrie F, Archer D, Bouchard C et al (2009) Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 16(5):923\u2013931","journal-title":"Menopause"},{"issue":"5","key":"3960_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1097\/gme.0b013e31819e8e2d","volume":"16","author":"F Labrie","year":"2009","unstructured":"Labrie F, Archer D, Bouchard C et al (2009) Intravaginal dehydroepiandrosterone (prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 16(5):907\u2013922","journal-title":"Menopause"},{"issue":"12","key":"3960_CR19","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1111\/jsm.13045","volume":"12","author":"F Labrie","year":"2015","unstructured":"Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, C\u00f4t\u00e9 I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur \u00c9, Members of the VVA Prasterone Research Group (2015) Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med 12(12):2401\u20132412. \n                    https:\/\/doi.org\/10.1111\/jsm.13045","journal-title":"J Sex Med"},{"key":"3960_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jsbmb.2013.08.002","volume":"138","author":"F Labrie","year":"2013","unstructured":"Labrie F, Martel C, Berube R et al (2013) Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol 138:359\u2013367. \n                    https:\/\/doi.org\/10.1016\/j.jsbmb.2013.08.002","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"3960_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/rej.2013.1425","volume":"16","author":"N Samaras","year":"2013","unstructured":"Samaras N, Samaras D, Frangos E, Forster A, Philippe JA (2013) Review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial? Rejuvenation Res 16(4):285\u2013294. \n                    https:\/\/doi.org\/10.1089\/rej.2013.1425","journal-title":"Rejuvenation Res"},{"issue":"2","key":"3960_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0004563213515190","volume":"51","author":"TT Hlaing","year":"2014","unstructured":"Hlaing TT, Compston JE (2014) Biochemical markers of bone turnover\u2014uses and limitations. Ann Clin Biochem 51(2):189\u2013202. \n                    https:\/\/doi.org\/10.1177\/0004563213515190","journal-title":"Ann Clin Biochem"},{"issue":"3","key":"3960_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S8756-3282(99)00175-1","volume":"2","author":"P Peris","year":"1999","unstructured":"Peris P, Alvarez L, Monegal A et al (1999) Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Bone 2(3):349\u2013353","journal-title":"Bone"},{"issue":"2","key":"3960_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3109\/13697137.2014.981520","volume":"18","author":"P Tuntiviriyapun","year":"2015","unstructured":"Tuntiviriyapun P, Panyakhamlerd K, Triratanachat S, Chatsuwan T, Chaikittisilpa S, Jaisamrarn U, Taechakraichana N (2015) Newly developed vaginal atrophy symptoms II and vaginal pH: a better correlation in vaginal atrophy? Climacteric 18(2):246\u2013251. \n                    https:\/\/doi.org\/10.3109\/13697137.2014.981520","journal-title":"Climacteric"},{"issue":"1","key":"3960_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00192-014-2464-0","volume":"26","author":"MA Weber","year":"2015","unstructured":"Weber MA, Limpens J, Roovers JPWR (2015) Assessment of vaginal atrophy: a review. Int Urogynecol J 26(1):15\u201328. \n                    https:\/\/doi.org\/10.1007\/s00192-014-2464-0","journal-title":"Int Urogynecol J"},{"issue":"5","key":"3960_CR26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/gme.0b013e31819e8930","volume":"16","author":"F Labrie","year":"2009","unstructured":"Labrie F, Archer D, Bouchard C et al (2009) Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 16(5):897\u2013906","journal-title":"Menopause"},{"key":"3960_CR27","doi-asserted-by":"crossref","unstructured":"Barton DL, Sloan JA, Shuster LT, et al Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance), J Clin Oncol, 2014 ASCO Annual Meeting Abstracts. Vol 32 No 15_suppl (May 20 Supplement), 2014: 9507","DOI":"10.1200\/jco.2014.32.15_suppl.9507"},{"issue":"6","key":"3960_CR28","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1210\/jcem-55-6-1124","volume":"55","author":"C Christiansen","year":"1982","unstructured":"Christiansen C, Christensen MS, Larsen NE, Transbol IB (1982) Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. J Clin Endocrinol Metab 55(6):1124\u20131130. \n                    https:\/\/doi.org\/10.1210\/jcem-55-6-1124","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"3960_CR29","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1096\/fj.06-7518com","volume":"21","author":"SN Birrell","year":"2007","unstructured":"Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD (2007) Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J 21(10):2285\u20132293. \n                    https:\/\/doi.org\/10.1096\/fj.06-7518com","journal-title":"FASEB J"},{"issue":"1","key":"3960_CR30","first-page":"177","volume":"2","author":"AM Traish","year":"2010","unstructured":"Traish AM, Fetten K, Miner M, Hansen ML, Guay A (2010) Testosterone and risk of breast cancer: appraisal of existing evidence. Horm Mol Biol Clin Invest 2(1):177\u2013190","journal-title":"Horm Mol Biol Clin Invest"},{"issue":"19","key":"3960_CR31","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.1158\/0008-5472.CAN-15-3372","volume":"76","author":"DG Hu","year":"2016","unstructured":"Hu DG, Selth LA, Tarulli GA et al (2016) Androgen and estrogen receptors in breast cancer coregulate human UDP-glucuronosyltransferases 2B15 and 2B17. Cancer Res 76(19):5881\u20135893","journal-title":"Cancer Res"},{"issue":"2","key":"3960_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2001-0031","volume":"24","author":"F Labrie","year":"2003","unstructured":"Labrie F, Luu-The V, Labrie C et al (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24(2):152\u2013182. \n                    https:\/\/doi.org\/10.1210\/er.2001-0031","journal-title":"Endocr Rev"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3960-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3960-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3960-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T15:09:47Z","timestamp":1589641787000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3960-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["3960"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3960-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]},"assertion":[{"value":"27 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was supported by the National Cancer Institute and the Breast Cancer Research Foundation. None of the authors have any conflicts of interest with either of these two funding agencies. The work is solely that of the authors and does not reflect the views of the funding agencies. The data is under the control of the Statistics and Data Management group of the Alliance and can be produced in support of the analysis described in this paper, if required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}